These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 20196808)

  • 1. Are FoxP3(+) cells involved in hyporesponsiveness to interferon/ribavirin therapy in chronic hepatitis C?
    Westin J; Hellstrand K; Dhillon AP; Lagging M;
    J Viral Hepat; 2011 Feb; 18(2):149-51. PubMed ID: 20196808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between regulatory T cells and the combination of pegylated interferon and ribavirin for the treatment of chronic hepatitis type C.
    Akiyama M; Ichikawa T; Miyaaki H; Motoyoshi Y; Takeshita S; Ozawa E; Miuma S; Shibata H; Taura N; Nakao K
    Intervirology; 2010; 53(3):154-60. PubMed ID: 20068349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin.
    Ancel D; Amiot X; Chaslin-Ferbus D; Hagege I; Garioud A; Girot R; Pol S; Grange JD
    Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):726-9. PubMed ID: 19404206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
    Böcher WO; Schuchmann M; Link R; Hillenbrand H; Rahman F; Sprinzl M; Mudter J; Löhr HF; Galle PR
    Liver Int; 2006 Apr; 26(3):319-25. PubMed ID: 16584394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of combined interferon-ribavirin in the treatment of chronic hepatitis C.
    Muhammad N; Jan MA; Rahman N
    J Coll Physicians Surg Pak; 2004 Nov; 14(11):651-3. PubMed ID: 15530272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.
    Hoofnagle JH; Ghany MG; Kleiner DE; Doo E; Heller T; Promrat K; Ong J; Khokhar F; Soza A; Herion D; Park Y; Everhart JE; Liang TJ
    Hepatology; 2003 Jul; 38(1):66-74. PubMed ID: 12829988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic hepatitis C with normal level of alanine-aminotransferase].
    Rossi G
    Recenti Prog Med; 2004 Nov; 95(11):509-11. PubMed ID: 15598087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
    Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
    Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hepatitis C virus: the first decade.
    Poynard T
    Semin Liver Dis; 2004; 24 Suppl 2():19-24. PubMed ID: 15346242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study.
    Alberti AB; Belli LS; Airoldi A; de Carlis L; Rondinara G; Minola E; Vangeli M; Cernuschi A; D'Amico M; Forti D; Pinzello G
    Liver Transpl; 2001 Oct; 7(10):870-6. PubMed ID: 11679985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans.
    Claassen MA; de Knegt RJ; Janssen HL; Boonstra A
    J Virol; 2011 Jun; 85(11):5323-30. PubMed ID: 21450832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic expression of MxA and OAS1 in an ex vivo liver slice assay independently predicts treatment outcomes in chronic hepatitis C.
    Cheng JC; Yeh YJ; Huang YH; Liang KH; Chang ML; Lin CY; Yeh CT
    J Viral Hepat; 2012 Feb; 19(2):e154-62. PubMed ID: 22239513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualization of antiviral treatment regimens for chronic hepatitis C.
    Paulon E; Naoumov NV
    Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):321-5. PubMed ID: 16538101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do DCs influence the antiviral effect of interferon/ribavirin by changing their profile during the therapy?
    Takahashi H; Zeniya M
    J Gastroenterol; 2006 Aug; 41(8):816-7. PubMed ID: 16988776
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.